Alberico L. Catapano is Full Professor of Pharmacology and Director of the Center of Epidemiology and Preventive Pharmacology at the University of Milan, Director of the Laboratory of Lipoproteins, Immunity and Atherosclerosis and the Center for the Study of Atherosclerosis at Bassini Hospital, and the atherosclerosis lipid clinic and genetics at IRCCS at Multimedica, Milan, Italy.

His main research interests include the study of atherosclerosis, lipids, lipoproteins and genetic dyslipidaemias, and he has made landmark observations regarding heat shock proteins and pentraxins in atherogenesis, on high-density lipoproteins in the modulation of the immune response, and on the identification of possible therapeutic targets by exploiting genetic information.
A past President of the European Atherosclerosis Society (EAS), Professor Catapano is currently Chairman of the EAS/European Society of Cardiology (ESC) guidelines for the treatment of dyslipoproteinaemias, President of the Italian Society of Clinical and Experimental Therapy, and a board member of the Italian Society for the Study of Atherosclerosis (SISA), as well as the General Director of the SISA Foundation, Co-editor of Atherosclerosis and Associate Editor of other scientific journals, he has authored more than 550 scientific papers in peer-reviewed journals including the The New England Journal of Medicine, The Lancet, Science, JACC, European Heart Journal, and Nature Reviews Cardiology.

He has been awarded the title of Commendatore della Repubblica for scientific merits in 2021 and is among the highly cited scientists according to Clarivate for 2019 and 2020. His H index is 104 according to Google Scholar.


LCN Lp(a) webinar series #5: Round table with the experts – How to use L(a) in practice, from the point of view of the cardiologist, the lipidologist, the diabetologist and the patientWebinars on-demandLCN Lp(a) webinar series #4: Therapeutic approaches - where we stand today and a look to the futureWebinars on-demandEAS Advanced Course – Rare Lipid Disorders - France & SwitzerlandWebinars on-demandLCN Lp(a) webinar series #3: Recommendations for Lp(a) screeningWebinars on-demandEAS Advanced Course – Rare Lipid Disorders - from LisbonWebinars on-demandIndustry Special Lecture - Discussion and Q&AIndustry Special Lecture90th EAS Congress 2022Lp(a): What we need to knowIndustry Special Lecture90th EAS Congress 2022IME Session - Should public health recommendations target Lp(a) measurements? - Discussion and Q&AIME Session - Should public health recommendations target Lp(a) measurements?90th EAS Congress 2022Debate: Who needs injectable therapies for cholesterol lowering? Statins and ezetimibe are enough for CVD prevention - Discussion and Q&A90th EAS Congress 2022ESC/EAS joint session: A deep dive into Prevention GLs with focus on dyslipidemiaOmega 3 fatty acids in cardiovascular prevention - Where do we stand? - Discussion and Q&A90th EAS Congress 2022Omega 3 fatty acids in cardiovascular prevention - Where do we stand?Implementation of the 2019 lipid guidelines-where are we now? - Discussion and Q&A90th EAS Congress 2022Implementation of the 2019 lipid guidelines-where are we now?Current available therapies - EzetimbeIntro to Clinical LipidologyBempedoic acid - Mechanism of actionIntro to Clinical LipidologyPCSK9 Inhibition - HIGHLIGHTS FROM RECENT PUBLICATIONSEAS AC in LipidologyLipid guidelines, where we stand?EAS AC in LipidologyIntroduction to the courseEAS AC in LipidologyClosing remarksEAS AC in LipidologyTraining Agenda OverviewAn Introduction to Clinical LipidologyThe new guidelines for dyslipidaemiaAn Introduction to Clinical LipidologyGuidelines - the goals why?An Introduction to Clinical LipidologyBempedoic Acid - Mechanism of actionAn Introduction to Clinical LipidologyWill aggressive LDL reduction prevent atherosclerosis?86th EAS Congress 2018The multifaceted aspects of CV prevention - from nutrition to therapy - Chair86th EAS Congress 2018Summary and introduction of guidelines85th EAS Congress 2017New recommendations and concepts in the new guidelines2019 ESC-EAS Dyslipidaemia GuidelinesA deep dive into EAS-ESC guidelines for dyslipidaemiasTherapeutic Approaches - The EAS way